Literature DB >> 32575123

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.

Florian Perner1,2, Jayant Y Gadrey1,2, Yijun Xiong1,2, Charles Hatton1,2, Benjamin K Eschle1,2, Andreas Weiss3, Frédéric Stauffer3, Christoph Gaul3, Ralph Tiedt3, Jennifer A Perry1,2, Scott A Armstrong1,2, Andrei V Krivtsov1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32575123      PMCID: PMC8209563          DOI: 10.1182/blood.2020006113

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  16 in total

1.  New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

Authors:  Frédéric Stauffer; Andreas Weiss; Clemens Scheufler; Henrik Möbitz; Christian Ragot; Kim S Beyer; Keith Calkins; Daniel Guthy; Michael Kiffe; Bernard Van Eerdenbrugh; Ralph Tiedt; Christoph Gaul
Journal:  ACS Med Chem Lett       Date:  2019-12-04       Impact factor: 4.345

2.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

4.  Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.

Authors:  Michael W M Kühn; Evelyn Song; Zhaohui Feng; Amit Sinha; Chun-Wei Chen; Aniruddha J Deshpande; Monica Cusan; Noushin Farnoud; Annalisa Mupo; Carolyn Grove; Richard Koche; James E Bradner; Elisa de Stanchina; George S Vassiliou; Takayuki Hoshii; Scott A Armstrong
Journal:  Cancer Discov       Date:  2016-08-17       Impact factor: 39.397

Review 5.  MLL translocations, histone modifications and leukaemia stem-cell development.

Authors:  Andrei V Krivtsov; Scott A Armstrong
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 6.  Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls.

Authors:  Nathan J Charles; Daniel F Boyer
Journal:  Arch Pathol Lab Med       Date:  2017-11       Impact factor: 5.534

7.  Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

Authors:  Aniruddha J Deshpande; Liying Chen; Maurizio Fazio; Amit U Sinha; Kathrin M Bernt; Deepti Banka; Stuart Dias; Jenny Chang; Edward J Olhava; Scott R Daigle; Victoria M Richon; Roy M Pollock; Scott A Armstrong
Journal:  Blood       Date:  2013-01-29       Impact factor: 22.113

8.  A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.

Authors:  Andrei V Krivtsov; Kathryn Evans; Jayant Y Gadrey; Benjamin K Eschle; Charlie Hatton; Hannah J Uckelmann; Kenneth N Ross; Florian Perner; Sarah N Olsen; Tara Pritchard; Lisa McDermott; Connor D Jones; Duohui Jing; Ali Braytee; Diego Chacon; Eric Earley; Brian M McKeever; David Claremon; Andrew J Gifford; Heather J Lee; Beverly A Teicher; John E Pimanda; Dominik Beck; Jennifer A Perry; Malcolm A Smith; Gerard M McGeehan; Richard B Lock; Scott A Armstrong
Journal:  Cancer Cell       Date:  2019-12-09       Impact factor: 31.743

9.  The MLL recombinome of acute leukemias in 2017.

Authors:  C Meyer; T Burmeister; D Gröger; G Tsaur; L Fechina; A Renneville; R Sutton; N C Venn; M Emerenciano; M S Pombo-de-Oliveira; C Barbieri Blunck; B Almeida Lopes; J Zuna; J Trka; P Ballerini; H Lapillonne; M De Braekeleer; G Cazzaniga; L Corral Abascal; V H J van der Velden; E Delabesse; T S Park; S H Oh; M L M Silva; T Lund-Aho; V Juvonen; A S Moore; O Heidenreich; J Vormoor; E Zerkalenkova; Y Olshanskaya; C Bueno; P Menendez; A Teigler-Schlegel; U Zur Stadt; J Lentes; G Göhring; A Kustanovich; O Aleinikova; B W Schäfer; S Kubetzko; H O Madsen; B Gruhn; X Duarte; P Gameiro; E Lippert; A Bidet; J M Cayuela; E Clappier; C N Alonso; C M Zwaan; M M van den Heuvel-Eibrink; S Izraeli; L Trakhtenbrot; P Archer; J Hancock; A Möricke; J Alten; M Schrappe; M Stanulla; S Strehl; A Attarbaschi; M Dworzak; O A Haas; R Panzer-Grümayer; L Sedék; T Szczepański; A Caye; L Suarez; H Cavé; R Marschalek
Journal:  Leukemia       Date:  2017-07-13       Impact factor: 11.528

10.  Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias.

Authors:  K Wang; M Sanchez-Martin; X Wang; K M Knapp; R Koche; L Vu; M K Nahas; J He; M Hadler; E M Stein; M S Tallman; A L Donahue; G M Frampton; D Lipson; S Roels; P J Stephens; E M Sanford; T Brennan; G A Otto; R Yelensky; V A Miller; M G Kharas; R L Levine; A Ferrando; S A Armstrong; A V Krivtsov
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528

View more
  8 in total

1.  MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape.

Authors:  Sarah Naomi Olsen; Laura Godfrey; James P Healy; Yoolim A Choi; Yan Kai; Charles Hatton; Florian Perner; Elena L Haarer; Behnam Nabet; Guo-Cheng Yuan; Scott A Armstrong
Journal:  Mol Cell       Date:  2022-03-03       Impact factor: 19.328

2.  IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.

Authors:  Brandon J Aubrey; Jevon A Cutler; Wallace Bourgeois; Katherine A Donovan; Shengqing Gu; Charlie Hatton; Sarah Perlee; Florian Perner; Homa Rahnamoun; Alexandra C P Theall; Jill A Henrich; Qian Zhu; Radosław P Nowak; Young Joon Kim; Salma Parvin; Anjali Cremer; Sarah Naomi Olsen; Nicholas A Eleuteri; Yana Pikman; Gerard M McGeehan; Kimberly Stegmaier; Anthony Letai; Eric S Fischer; X Shirley Liu; Scott A Armstrong
Journal:  Nat Cancer       Date:  2022-05-09

Review 3.  Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics.

Authors:  Michelle Y Wang; Priscilla Liow; Maria I Tarazona Guzman; Jun Qi
Journal:  ACS Chem Biol       Date:  2022-04-01       Impact factor: 4.634

Review 4.  Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation.

Authors:  Florian Perner; Scott A Armstrong
Journal:  Cells       Date:  2020-12-21       Impact factor: 6.600

Review 5.  Differentiation therapy for myeloid malignancies: beyond cytotoxicity.

Authors:  Ryan J Stubbins; Aly Karsan
Journal:  Blood Cancer J       Date:  2021-12-04       Impact factor: 11.037

6.  Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia.

Authors:  Derek H Janssens; Michael P Meers; Steven J Wu; Ekaterina Babaeva; Soheil Meshinchi; Jay F Sarthy; Kami Ahmad; Steven Henikoff
Journal:  Nat Genet       Date:  2021-10-18       Impact factor: 41.307

Review 7.  Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors.

Authors:  Elena Alexandrova; Annamaria Salvati; Giovanni Pecoraro; Jessica Lamberti; Viola Melone; Assunta Sellitto; Francesca Rizzo; Giorgio Giurato; Roberta Tarallo; Giovanni Nassa; Alessandro Weisz
Journal:  Front Genet       Date:  2022-04-13       Impact factor: 4.772

8.  Targeting Chromatin Regulation in Acute Myeloid Leukemia.

Authors:  Simon E Richardson; Brian J P Huntly
Journal:  Hemasphere       Date:  2021-06-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.